Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 12/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 3/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977366 | 0.89 | BACE1 (0.33) | BACE1 | |
| SCHEMBL977224 | 0.88 | F2 (0.34) | BACE1 | |
| SCHEMBL977905 | 0.85 | ACHE (0.40) | PDE2AACHEEPHX2 | |
| SCHEMBL975841 | 0.84 | ACHE (0.41) | PDE2AACHE | |
| SCHEMBL977296 | 0.83 | CA1 (0.36) | BACE1 | |
| SCHEMBL976414 | 0.82 | UTS2R (0.38) | — | |
| SCHEMBL977101 | 0.81 | HPGDS (0.39) | BACE1 | |
| SCHEMBL977628 | 0.81 | F2 (0.36) | — | |
| SCHEMBL976435 | 0.81 | ACHE (0.37) | PDE2AACHEUSP30HRH3EPHX2 | |
| SCHEMBL977060 | 0.80 | PDE2A (0.35) | PDE2ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234966-B1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SA (FR) | 2013-09-11 | — | — | EP | claimed |
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | claimed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI (FR) | 2013-09-12 | — | — | US | disclosed |
| EP-2234966-B1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SA (FR) | 2013-09-11 | — | — | EP | disclosed |
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | PDE2A 181/4885ACHE 529/4885USP30 1495/4885 |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | PDE2A 181/4885ACHE 529/4885USP30 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.